search
Back to results

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

Primary Purpose

Congenital Pseudarthrosis of Tibia

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
NVD-003, an autologous 3D scaffold free osteogenic graft
Sponsored by
Novadip Biosciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congenital Pseudarthrosis of Tibia focused on measuring Tissue Engineered Therapy, bone graft, autologous, pediatric, congenital, non-union, pseudarthrosis, Cellular therapy

Eligibility Criteria

2 Years - 8 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosed with congenital pseudarthrosis of the tibia (with or without NF1) and presenting with a non-healing Paley type 3 or 4 fracture. Minimum weight of 5kg/11lbs. Maximum 2 previous failed surgical orthopaedic interventions to treat the primary CPT fracture. Acceptable serology and molecular test results excluding the presence of viruses Satisfactory general health condition to undergo surgeries (ATC and GS) with anaesthesia as per local standards. The patient's parent(s) and/or legal guardian(s) provided written informed consent and accepted the participation of the patient in the trial. Exclusion Criteria: Bilateral CPT. Presence of CPT without a fracture of the tibia (Paley type 1 and 2). More than 2 failed surgical attempt(s) to treat the primary tibial fracture. Evidence of plexiform neurofibroma of any size or nodular fibroma ≥ 1.2in/3cm on the ipsilateral leg. Clinically significant infection at the target grafting site or systemic infection. Presence of clinically significant hematologic, renal, hepatic, and coagulation laboratory abnormalities (i.e., CBC, PT/INR, Chem-7, and LFTs, etc.). Presence of any auto-immune disease, with exception of well controlled diabetes type 1 or auto-immune thyroid disorders. Any history of experimental therapy with another investigational drug within 60 days prior to screening. Presence of active tumour. Documented metabolic bone disease or any disorder, such as but not limited to osteogenesis imperfecta and osteomalacia, that could interfere with the bone healing and bone metabolism. Chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, anticoagulant therapies, immunosuppressant therapy or immunotherapy.

Sites / Locations

  • Adult/Pediatric Limb Lengthening and Reconstruction - International Center for Limb Lengthening - Rubin Institute for Advanced Orthopedics BaltimoreRecruiting
  • Cliniques Universitaires Saint-LucRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NVD-003 bone graft implant

Arm Description

The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages Stage 1: A screening, adipose tissue collection & NVD 003 manufacturing period. Stage 2: Grafting surgery and 12-month post-GS follow-up period. Stage 3: long-term safety follow-up period (from post-month 12 to month 24).

Outcomes

Primary Outcome Measures

Primary objective: safety short (≤3 months) and mid long-term (>3-12 months): : Descriptive analysis
Assess number of patients with NVD-003 related (S)AEs

Secondary Outcome Measures

Long term Safety long-term (>12-24 months): Descriptive analysis
Assess number of patients with NVD-003 related SAEs
Tibial length evaluation
Assess evolution tibial length (using CT-Scan)
Bone formation
Assess changes in bone formation (Using Lane and Sandhu Scoring on CT-Scan)
Bone remodeling
Assess changes in bone remodeling (using Lane and Sandhu Scoring on CT-scan) Based on Dual Energy CT-scan (DECT or Spectral CT), information of low- and high-energy photons is collected, allowing to uncover differences in energy-dependent attenuation, facilitating composition of NVD 003 and surrounding tissue and define bone mineral density) at 3-, 6-, and 12-months post-GS
Bone union
Assess changes in bone union (using Lane and Sandhu Scoring on CT-scan)

Full Information

First Posted
October 26, 2022
Last Updated
February 9, 2023
Sponsor
Novadip Biosciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05693558
Brief Title
NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia
Official Title
A Proof-of-concept Study With NVD-003, an Autologous Osteogenic Bone Graft, in the Treatment of Congenital Pseudarthrosis of the Tibia in Pediatric Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 24, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novadip Biosciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.
Detailed Description
Congenital pseudarthrosis is a rare disorder of unknown aetiology and variable history that manifests itself as a non-union or pseudarthrosis of fractures that develop spontaneously or following minor trauma. It can be defined as a disorder of the diaphysis which is revealed by either pseudarthrosis at birth or by a pathological fracture presenting in bone with modifications such as bowing, narrowing of the medullary canal or a cyst. Although uncommon, CPT is the most frequently observed type of congenital pseudarthrosis. Its incidence is reported to be between 1:140,000 to 1:250,000 live births. Autologous bone grafting is considered the gold standard approach as this material vascularizes and integrates with surrounding bone, minimizing the risk of infection, dislodgement, or break-down. NVD-003 is a scaffold free 3D osteogenic graft derived from autologous adipose stem cells which become embedded in their extracellular matrix and combined with hydroxyapatite/beta-tricalcium phosphate (HA/βTCP) particles. NVD-003 is intended to promote bone formation, supporting the physiological bone healing process in severe pathophysiological conditions such as hypoxia, lack of mineralized callus formation, bone resorption and low osteogenicity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Pseudarthrosis of Tibia
Keywords
Tissue Engineered Therapy, bone graft, autologous, pediatric, congenital, non-union, pseudarthrosis, Cellular therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NVD-003 bone graft implant
Arm Type
Experimental
Arm Description
The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages Stage 1: A screening, adipose tissue collection & NVD 003 manufacturing period. Stage 2: Grafting surgery and 12-month post-GS follow-up period. Stage 3: long-term safety follow-up period (from post-month 12 to month 24).
Intervention Type
Biological
Intervention Name(s)
NVD-003, an autologous 3D scaffold free osteogenic graft
Intervention Description
Bone correction and grafting surgery
Primary Outcome Measure Information:
Title
Primary objective: safety short (≤3 months) and mid long-term (>3-12 months): : Descriptive analysis
Description
Assess number of patients with NVD-003 related (S)AEs
Time Frame
Up to 12 months post-grafting surgery
Secondary Outcome Measure Information:
Title
Long term Safety long-term (>12-24 months): Descriptive analysis
Description
Assess number of patients with NVD-003 related SAEs
Time Frame
12-24 months post grafting surgery
Title
Tibial length evaluation
Description
Assess evolution tibial length (using CT-Scan)
Time Frame
3-, 6-, 12- and 24-months post-GS
Title
Bone formation
Description
Assess changes in bone formation (Using Lane and Sandhu Scoring on CT-Scan)
Time Frame
3-, 6-, 12- and 24-months post-GS
Title
Bone remodeling
Description
Assess changes in bone remodeling (using Lane and Sandhu Scoring on CT-scan) Based on Dual Energy CT-scan (DECT or Spectral CT), information of low- and high-energy photons is collected, allowing to uncover differences in energy-dependent attenuation, facilitating composition of NVD 003 and surrounding tissue and define bone mineral density) at 3-, 6-, and 12-months post-GS
Time Frame
3-, 6-, 12- and 24-months post-GS
Title
Bone union
Description
Assess changes in bone union (using Lane and Sandhu Scoring on CT-scan)
Time Frame
3-, 6-, 12- and 24-months post-GS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
8 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with congenital pseudarthrosis of the tibia (with or without NF1) and presenting with a non-healing Paley type 3 or 4 fracture. Minimum weight of 5kg/11lbs. Maximum 2 previous failed surgical orthopaedic interventions to treat the primary CPT fracture. Acceptable serology and molecular test results excluding the presence of viruses Satisfactory general health condition to undergo surgeries (ATC and GS) with anaesthesia as per local standards. The patient's parent(s) and/or legal guardian(s) provided written informed consent and accepted the participation of the patient in the trial. Exclusion Criteria: Bilateral CPT. Presence of CPT without a fracture of the tibia (Paley type 1 and 2). More than 2 failed surgical attempt(s) to treat the primary tibial fracture. Evidence of plexiform neurofibroma of any size or nodular fibroma ≥ 1.2in/3cm on the ipsilateral leg. Clinically significant infection at the target grafting site or systemic infection. Presence of clinically significant hematologic, renal, hepatic, and coagulation laboratory abnormalities (i.e., CBC, PT/INR, Chem-7, and LFTs, etc.). Presence of any auto-immune disease, with exception of well controlled diabetes type 1 or auto-immune thyroid disorders. Any history of experimental therapy with another investigational drug within 60 days prior to screening. Presence of active tumour. Documented metabolic bone disease or any disorder, such as but not limited to osteogenesis imperfecta and osteomalacia, that could interfere with the bone healing and bone metabolism. Chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, anticoagulant therapies, immunosuppressant therapy or immunotherapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Denis Dufrane, MD
Phone
003210827054
Email
clinical@novadip.com
First Name & Middle Initial & Last Name or Official Title & Degree
Houda Khamis, PhD
Phone
003210827054
Email
regulatory@novadip.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip McClure, MD
Organizational Affiliation
International Center for Limb Lengthening Baltimore
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Pierre-Louis Docquier
Organizational Affiliation
UCL St.Luc Brussels
Official's Role
Principal Investigator
Facility Information:
Facility Name
Adult/Pediatric Limb Lengthening and Reconstruction - International Center for Limb Lengthening - Rubin Institute for Advanced Orthopedics Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philip McClure, MD
First Name & Middle Initial & Last Name & Degree
Martin Gesheff
Email
Mgesheff@lifebridgehealth.org
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre-Louis Docquier, MD
Email
pierre-louis.docquier@saintluc.uclouvain.be

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30996736
Citation
Paley D. Congenital pseudarthrosis of the tibia: biological and biomechanical considerations to achieve union and prevent refracture. J Child Orthop. 2019 Apr 1;13(2):120-133. doi: 10.1302/1863-2548.13.180147.
Results Reference
background
PubMed Identifier
29113460
Citation
Dufrane D. Impact of Age on Human Adipose Stem Cells for Bone Tissue Engineering. Cell Transplant. 2017 Sep;26(9):1496-1504. doi: 10.1177/0963689717721203.
Results Reference
background

Learn more about this trial

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

We'll reach out to this number within 24 hrs